Officials at the Generic Pharmaceutical Association (GPhA) are wasting no time in letting incoming FDA Commissioner Andrew von Eschenbach, MD, know what they will be expecting from him. In a statement welcoming Dr. von Eschenbach to the FDA, GPhA President and Chief Executive Officer Kathleen Jaeger said that the appointment of "a permanent commissioner is an absolute necessity at a federal agency that has such a direct impact on the health and well-being of America's citizens."
Jaeger urged the new FDA chief to move quickly "to appropriately address important issues, such as an abbreviated approval pathway for generic biopharmaceuticals, authorized generics, the timely approval of generic medicines, and increased funding for the Office of Generic Drugs."
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs